Bortezomib

Bortezomib-based treatment of acute antibody-mediated rejection: a case report

Q. Wang, Li, X. L., Xu, X. G., Shi, B. Y., Zhang, Z. M., Li, Z. L., Han, Y., Zhou, W. Q., Chen, C. Q., Cai, M., and Zhang, X., Bortezomib-based treatment of acute antibody-mediated rejection: a case report, vol. 14, pp. 17951-17958, 2015.

Antibody-mediated rejection (AMR) is an important factor affecting survival after renal transplantation. A highly selective proteasome inhibitor, bortezomib, clears activated plasma cells from the body and has important therapeutic effect on AMR. We investigated the effects of bortezomib on AMR in a patient after a second renal transplant. Biopsy confirmed the diagnosis of mixed cellular rejection and AMR. Bortezomib was administered on day 1 (1.3 mg/m2), day 4 (1.0 mg/m2), and day 8 (1.0 mg/m2).

Apoptotic effects of proteasome and histone deacetylase inhibitors in prostate cancer cell lines

I. Kiliccioglu, Konac, E., Varol, N., Gurocak, S., and C. Bilen, Y., Apoptotic effects of proteasome and histone deacetylase inhibitors in prostate cancer cell lines, vol. 13, pp. 3721-3731, 2014.

Prostate cancer is one of the most common types of urological cancers. Despite the implementation of effective radiotherapy and chemotherapy methods, prostate cancer cells can still show resistance to treatment. In recent years, a combination of proteasome and histone deacetylase inhibitors has been used to treat various malignancies.

Subscribe to Bortezomib